Hidratación por vía subcutánea en pacientes con cáncer avanzado / Subcutaneous hydration in patients with advanced cancer
Rev. Med. Univ. Navarra
; 52(3): 3-8, jul.-sept. 2008. tab
Article
en Es
| IBECS
| ID: ibc-69311
Biblioteca responsable:
ES15.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Introduction: Subcutaneous infusion allows the administration of parenteral treatments. However, subcutaneous hydration is exceptional in ourenvironment. We developed this trial in order to assess the feasibility of such hydration in cancer patients, the procedures and potential complications.Patients, material and methods: We included dehydrated terminally ill cancer patients and patients at risk of developing dehydration from the Palliative Care Unit of The Grey Nuns Hospital, Edmonton (Canada) and Hospital Universitario de Valladolid (Spain). They received subcutaneous hydration; the volume and rhythm of infusion were adapted to each patient.Results: We performed 101 clyses in 33 patients (Edmonton 24; Valladolid 9), with a total of 314 days of infusion. Volume infused was 1,000 cc/day over a median of three days (1 to 21 days) and a rhythm of 20 cc/hour. Clyses were changed every three days (1 to 15 days),mainly because of fl uid retention in the puncture area. Two patients required hyaluronidase. There were differences between Hospitals in characteristics of patients (worse prognosis in the Spanish group) andconditions of infusion (higher volume and duration in Canadians). The incidence of complications was low, being similar in both groups.Conclusions: Subcutaneous hydration of terminally ill cancer patients is easy and seems to be free of severe complications (AU)
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Deshidratación
/
Fluidoterapia
/
Inyecciones Subcutáneas
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
Es
Revista:
Rev. Med. Univ. Navarra
Año:
2008
Tipo del documento:
Article